Tau antibody
![Research Use Only](static/images/certificates/ruo.jpg)
GTX116044
ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry
Product group Antibodies
ReactivityHuman
TargetMAPT
Overview
- SupplierGeneTex
- Product NameTau antibody
- Delivery Days Customer9
- Application Supplier NoteWB: 1:500-1:3000. ICC/IF: 1:100-1:1000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration1.03 mg/ml
- ConjugateUnconjugated
- FormulationLiquid
- Gene ID4137
- Target nameMAPT
- Target descriptionmicrotubule associated protein tau
- Target synonymsDDPAC; FTDP-17; G protein beta1/gamma2 subunit-interacting factor 1; MAPTL; microtubule-associated protein tau; MSTD; MTBT1; MTBT2; neurofibrillary tangle protein; paired helical filament-tau; PHF-tau; PPND; PPP1R103; protein phosphatase 1, regulatory subunit 103; TAU; tau-40
- HostRabbit
- IsotypeIgG
- Protein IDP10636
- Protein NameMicrotubule-associated protein tau
- Scientific DescriptionThis gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimers disease, Picks disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq]
- ReactivityHuman
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Neuronal Transdifferentiation Potential of Human Mesenchymal Stem Cells from Neonatal and Adult Sources by a Small Molecule Cocktail. Cortes-Medina LV et al., 2019, Stem Cells IntRead more
- A Fas Ligand (FasL)-Fused Humanized Antibody Against Tumor-Associated Glycoprotein 72 Selectively Exhibits the Cytotoxic Effect Against Oral Cancer Cells with a Low FasL/Fas Ratio. Chien MH et al., 2017 Jun, Mol Cancer TherRead more